We would like to comment on the article from Drs. Ishida and colleagues, titled “Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a retrospective cohort study at a single transplant institute in Japan.”1 Ishida and colleagues found that the percentage of responsive viral fragments varied substantially between patients and showed no consistency in the kidney transplant group, whereas the mean fluorescence intensity of individual fragments showed a trend in the control group.1
We agree that a kidney transplant recipient’s immune response may differ from that of a healthy person. Although their study may provide important information, it should also take into account the possibility of a confounding underlying element. Because of immunologic anomalies, COVID-19 may become asymptomatic, making it more difficult to establish the vaccine’s efficacy in prior trials. In general, asymptomatic COVID-19 is not uncommon.2 The possibility of asymptomatic COVID-19 must be ruled out before a firm judgment can be reached.3 Whether COVID-19 presents as asymptomatic or symptomatic, immunization can establish immunity, although asymptomatic infection can dramatically affect the measured immunologic status.
Volume : 20
Issue : 11
Pages : 1048 - 1048
DOI : 10.6002/ect.2022.0176
From the 1Private Academic Consultant, Bangkok Thailand; and 2Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria
Acknowledgements: The authors have not received any funding or grants in support of the presented research or for the preparation of this work and have no declarations of potential conflicts of interest.
Corresponding author: Rujittika Mungmunpuntipantip, Private Academic Consultant, Bangkok Thailand